Why This Question Matters

Families facing Alzheimer’s disease understandably want simple answers. Memory loss is frightening, and cognitive decline can affect independence, relationships, safety, and quality of life.

Unfortunately, Alzheimer’s disease is not a simple condition. The brain is influenced by many biological systems working together at the same time.

These systems include inflammation, metabolism, hormones, blood flow, sleep, immune function, nutrition, environmental exposures, and neural network activity.

When several of these systems become disrupted, cognitive performance can suffer. Therefore, a single-target explanation may never have been enough.

The Original Amyloid Hypothesis

The amyloid hypothesis became dominant because researchers repeatedly observed amyloid plaques in the brains of people diagnosed with Alzheimer’s disease.

The logic seemed compelling: Alzheimer’s patients have amyloid plaque. Therefore, amyloid causes Alzheimer’s disease. If amyloid is removed, the condition should improve.

That theory drove billions of dollars in research funding and pharmaceutical development. Entire treatment strategies were built around it.

However, there was always one important question. Was amyloid actually causing Alzheimer’s disease, or was it appearing alongside it?

That distinction matters because association is not the same as root cause.

Correlation Does Not Always Mean Cause

One of the most common mistakes in science is confusing correlation with causation.

Consider a simple example. Every time firefighters arrive at a burning building, fire trucks are present. Yet no one believes fire trucks caused the fire.

The same principle applies to amyloid plaque. The fact that amyloid is present in Alzheimer’s disease does not automatically prove it is the original cause of the disease.

Another explanation is possible. Amyloid may be part of the brain’s response to injury rather than the original trigger.

That possibility is now receiving much more attention.

Could Amyloid Be the Brain’s Protective Response?

One of the most important ideas in modern cognitive medicine is that amyloid may function as part of the brain’s immune response.

In this model, amyloid is not necessarily the original problem. Instead, the brain may produce amyloid in response to ongoing stressors.

These stressors may include chronic inflammation, infections, metabolic dysfunction, oxidative stress, vascular injury, environmental toxins, poor sleep, or other threats to brain health.

In other words, the brain may be producing amyloid for a reason.

If that is true, then simply removing amyloid may not address the processes that caused the brain to produce it in the first place.

The Smoke Detector Problem

At The Carroll Institute, we often explain amyloid using a smoke detector analogy.

Imagine a house catches fire. The smoke detector begins sounding an alarm.

The alarm is real. The alarm is loud. The alarm is associated with the fire.

However, disabling the smoke detector does not stop the fire. The fire continues burning.

In the same way, amyloid may be acting like the smoke detector. It may signal that something is wrong inside the brain.

Removing amyloid without addressing inflammation, metabolic dysfunction, toxins, infections, vascular disease, sleep disruption, or other contributors may reduce a visible marker while leaving the underlying problem untouched.

That may help explain why amyloid-targeting drugs have produced limited clinical improvement.

What Lecanemab and Donanemab Taught Us

Recent amyloid-removing drugs created a real-world test of the amyloid hypothesis.

The results were revealing. Researchers successfully reduced amyloid burden in the brain. That part worked.

However, patients generally did not regain lost memory or return to normal cognitive function. Instead, decline continued at a somewhat slower pace.

For many researchers and families, this created a new question.

If amyloid is truly the primary cause of Alzheimer’s disease, why does removing it not produce dramatically greater improvement?

The most reasonable conclusion may be that amyloid plays a role, but it is unlikely to explain the entire disease process.

What Patients Should Learn From This

The lesson is not that amyloid is irrelevant.

The lesson is that Alzheimer’s disease appears to be much more complex than a single protein.

Research increasingly points toward a combination of contributors. These may include neuroinflammation, insulin resistance, poor sleep, hormonal imbalance, vascular dysfunction, nutritional deficiencies, environmental toxins, chronic infections, and impaired neuroplasticity.

Every patient presents a unique combination of these factors. As a result, one-size-fits-all treatment approaches often fall short.

This is why a broader, more personalized model is needed.

Why the EVANTHEA Study Matters

The EVANTHEA Study took a very different approach.

Instead of focusing on a single target, researchers evaluated multiple contributors at the same time. These included inflammation, metabolism, nutrition, hormones, sleep, exercise, stress, and cognitive stimulation.

The study demonstrated measurable improvements in cognitive outcomes using a personalized Precision Medicine strategy.

That finding reinforces an important principle: complex diseases often require comprehensive solutions.

The Carroll Cognitive Method™ Perspective

At The Carroll Institute, we do not view Alzheimer’s disease as simply an amyloid problem.

We view it as a systems problem.

That does not mean amyloid is unimportant. It means amyloid is unlikely to be sufficient as an explanation.

The Carroll Cognitive Method™ combines Precision Medicine, Functional Medicine, and Functional Neurology because cognitive decline is influenced by multiple biological systems at once.

Precision Medicine helps identify contributors. Functional Medicine helps address them. Functional Neurology helps evaluate and rehabilitate affected brain networks through neuroplasticity-based strategies.

Our goal is not merely to measure amyloid. Our goal is to understand why the brain is struggling and how we can help it function better.

Next Steps

One of the biggest lessons from modern Alzheimer’s research is that simple explanations rarely solve complex problems.

Amyloid may matter. However, the evidence increasingly suggests that amyloid is unlikely to be the whole story.

The future of cognitive medicine will likely involve understanding inflammation, metabolism, vascular health, sleep, hormones, toxins, and brain network function together rather than focusing on one factor alone.

If you or a loved one are experiencing memory loss, Mild Cognitive Impairment, early Alzheimer’s disease, or unexplained cognitive decline, a comprehensive evaluation may help identify contributors that have not been fully investigated.

If you are in Sarasota, the Gulf Coast region, or looking for a deeper evaluation of memory loss, brain fog, or cognitive performance, Book a discovery call to see if this is a fit for you. Or learn more about the Carroll Cognitive Method™ and ReCODE program.

Sources & Citations

• Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s – Simon & Schuster
• Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled Trial – Preprints.org
• FDA Approves Treatment for Adults with Alzheimer’s Disease – U.S. Food & Drug Administration
• Alzheimer’s Disease Fact Sheet – National Institute on Aging
• ReCODE-Based Precision Medicine Framework – The Carroll Institute

Medically reviewed by Dr. Garland Glenn, DC, PhD, AFMC

Last updated: June 10, 2026

This content is for educational purposes and does not substitute personalized medical advice.